Relationship between urinary pyridinium cross-links, disease activity and disease subsets of ankylosing spondylitis

Rheumatology

Volumn 38, Issue 1, 1999, Pages 21-27

  Toussirot, E ^a   Ricard Blum, S ^b   Dumoulin, G ^a   Cedoz, J P ^a   Wendling, D ^a  

^a UNIVERSITY HOSPITAL JEAN MINJOZ   (France)

^b INSTITUT DE BIOLOGIE STRUCTURALE   (France)

Author keywords

Ankylosing spondylitis; Deoxpyridinoline; Osteoporosis; Pyridinoline

Indexed keywords

CALCIFEDIOL; CALCIUM ION; COLLAGEN TYPE 1; DEOXYPYRIDINOLINE; MARKER; OSTEOCALCIN; PARATHYROID HORMONE; PYRIDINIUM DERIVATIVE; PYRIDINOLINE;

ADULT; ANKYLOSING SPONDYLITIS; ARTICLE; BONE DENSITY; BONE METABOLISM; BONE MINERAL; CALCIUM BLOOD LEVEL; CLINICAL ARTICLE; CONTROLLED STUDY; CROSS LINKING; DISEASE ACTIVITY; DISEASE DURATION; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; FEMUR NECK; GENDER; HUMAN; LUMBAR SPINE; MALE; OSTEOLYSIS; PARATHYROID HORMONE BLOOD LEVEL; PRIORITY JOURNAL; URINE LEVEL;

ADULT; AGED; AMINO ACIDS; BIOLOGICAL MARKERS; BLOOD SEDIMENTATION; BONE DENSITY; COLLAGEN; COLLAGEN TYPE I; CROSS-SECTIONAL STUDIES; DENSITOMETRY, X-RAY; FEMALE; FEMUR NECK; HUMANS; LUMBAR VERTEBRAE; MALE; MIDDLE AGED; PEPTIDES; SPONDYLITIS, ANKYLOSING;

EID: 0032736158     PISSN: 14620324     EISSN: None     Source Type: Journal    
DOI: 10.1093/rheumatology/38.1.21     Document Type: Article

References (27)

1. Toussirot E, Wendling D. L'ostéoporose de la spondylarthrite ankylosante. Presse Med 1996;25:720-4.
2. Ralston SH, Urquhart GDK, Brzeski M, Sturrock RD. Prevalence of vertebral compression fractures due to osteoporosis in ankylosing spondylitis. Br Med J 1990;300:563-5.
3. Cooper C, Carbone L, Michet CJ, Atkinson EJ, O'Fallon WM, Melton LJ. Fracture risk in patients with ankylosing spondylitis: a population based study. J Rheumatol 1994;21:1877-82.
4. Devogelaer JP, Maldague B, Malghem J, Nagant de Deuxchaisnes C. Appendicular and vertebral bone mass in ankylosing spondylitis. A comparison of plain radiographs with single and dual photon absorptiometry and with quantitative computed tomography. Arthritis Rheum 1992;35:1062-7.
5. Will R, Bhalla AK, Palmer R, Ring F, Calin A. Osteoporosis in early ankylosing spondylitis: a primary pathological event? Lancet 1989;2:1483-5.
6. Uebelhart D, Gineyts E, Chapuy MC, Delmas PD. Urinary excretion of pyridinium crosslinks: a new marker of bone resorption in metabolic bone disease. Bone Miner 1990;8:87-96.
7. Risteli L, Risteli J. Biochemical markers of bone metabolism. Ann Med 1993;25:385-93.
8. Hanson DA, Weis MAE, Bollen AM, Maslan SL, Singer FR, Re DR. A specific immunoassay for monitoring human bone resorption: quantitation of type I collagen cross-linked N-telopeptides in urine. J Bone Miner Res 1992;7:1251-8.
9. Risteli J, Elomaa I, Niemi S, Novamo A, Risteli L. Radioimmunoassay for the pyridinoline cross-linked carboxy-terminal telopeptide of type I collagen: a new serum marker of bone collagen degradation. Clin Chem 1993;39:635-40.
10. Rosen HN, Dresner-Pollak R, Moses AC, Rosenblatt M, Zeind AJ, Clemens JD et al. Specificity of urinary excretion of cross-linked N telopeptides of type I collagen as a marker of bone resorption. Calcif Tissue Int 1994;54:26-9.
11. Bonde M, Qvist P, Fledelius C, Riis BJ, Christiansen C. Applications of an enzyme immunoassay for a new marker of bone resorption (CrossLaps): follow-up on hormone replacement therapy and osteoporosis risk assessment. J Clin Endocrinol Metab 1995;80:864-8.
12. Garnero P, Gineyts E, Schaffer AV, Seaman J, Delmas PD. Measurement of urinary excretion of nonisomerized and β-isomerized forms of type I collagen breakdown products to monitor the effects of the bisphosphonate zolendronate in Paget's disease. Arthritis Rheum 1998;41:354-60.
13. Seibel M, Duncan A, Robins SP. Urinary hydroxypyridinium crosslinks provide indices of cartilage and bone involvement in arthritic diseases. J Rheumatol 1989; 16:964-70.
14. Hellio LE, Graverand MP, Tron AM, Ichou M, Dallard MC, Richard M et al. Assessment of urinary hydroxypyridinium cross-links measurement in osteoarthritis. Br J Rheumatol 1996;35:1091-5.
15. Van Der Linden S, Valkenburg HA, Cats A. Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New-York criteria. Arthritis Rheum 1984;27:361-8.
16. Garrett S, Jenkinson T, Kennedy LG, Whitelock H, Gaisford P, Calin A. A new approach to defining disease status in ankylosing spondylitis: the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 1994;21:2286-91.
17. Gomez B, Ardakani S, Evans BJ, Merrell LD, Jenkins DK, Kung VT. Monoclonal antibody assay for free pyridinium crosslinks. Clin Chem 1996;42:1168-75.
18. Robins SP, Woigte H, Hesley R, Ju J, Seyedin S, Seibel MJ. Direct, enzyme-linked immunoassay for urinary deoxypyridinoline as a specific marker for measuring bone resorption. J Bone Miner Res 1994;9:1643-9.
19. Bonde H, Qvist P, Fledelius C, Riis BJ, Christiansen C. Immunoassay for quantifying type I collagen degradation products in urine evaluated. Clin Chem 1994;40:2022-5.
20. Gough AKS, Peel NFA, Eastell R, Holder RL, Lilley J, Emery P. Excretion of pyridinium crosslinks correlates with disease activity and appendicular bone loss in early rheumatoid arthritis. Ann Rheum Dis 1994;53:14-7.
21. Sinigaglia L, Varenna M, Binelli L, Bartucci F, Arrigoni M, Ferrara R et al. Urinary and synovial pyridinium crosslink concentrations in patients with rheumatoid arthritis and osteoarthritis. Ann Rheum Dis 1995; 54:144-7.
22. Astbury C, Bird HA, McLaren AM, Robins SP. Urinary excretion of pyridinium crosslinks of collagen correlated with joint damage in arthritis. Br J Rheumatol 1994;33:11-5.
23. Marhoffer W, Stracke H, Masoud I, Scheja M, Graef V, Bolten W et al. Evidence of impaired cartilage/bone turnover in patients with active ankylosing spondylitis. Ann Rheum Dis 1995;54:556-9.
24. Macdonald AG, Birkinshaw G, Durham B, Bucknall RC, Fraser WD. Biochemical markers of bone turnover in seronegative spondylarthropathy: relationship to disease activity. Br J Rheumatol 1997;35:50-3.
25. Bronson WD, Walker SE, Hillman LS, Keisler D, Hoyt T, Allen SH. Bone mineral density and biochemical markers of bone metabolism in ankylosing spondylitis. J Rheumatol 1998;25:929-35.
26. Wendung D, Dumoulin G. Spondylarthrite ankylosante et paramètres phosphocalciques. Rev Rheum 1991; 58:279-81.
27. Franck H, Keck E. Serum osteocalcin and vitamin D metabolites in patients with ankylosing spondylitis. Ann Rheum Dis 1993;52:343-6.